AR024746A1 - Androgenos oralmente activos. - Google Patents

Androgenos oralmente activos.

Info

Publication number
AR024746A1
AR024746A1 ARP000103625A ARP000103625A AR024746A1 AR 024746 A1 AR024746 A1 AR 024746A1 AR P000103625 A ARP000103625 A AR P000103625A AR P000103625 A ARP000103625 A AR P000103625A AR 024746 A1 AR024746 A1 AR 024746A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydrogen
oralally
active androgens
acyl
Prior art date
Application number
ARP000103625A
Other languages
English (en)
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of AR024746A1 publication Critical patent/AR024746A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051Estrane derivatives
    • C07J1/0066Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0074Esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16Masculine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051Estrane derivatives
    • C07J1/0066Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Nuevos androgenos oralmente activos son derivados de delta14-nandrolona 7alfa-sustituidos. Los compuestos satisfacen la formula general 1 donde R1 es O,(H, H), (H, OR), NOR, siendo R hidrogeno, (C1-6)alquilo o (C1-.6)acilo; R2 se selecciona delgrupo consistente en (C2-4)alquilo, (C2-4)alquenilo o(C2-4)alquinilo, cada uno opcionalmente sustituido por halogeno; o R2 es ciclopropilo o ciclopropenilo, cada uno opcionalmente sustituido por (C1-2)alquilo ohalogeno; R3 es hidrogeno,(C1-2)alquilo o e tenilo; R4 es (C1-2) alquilo; R5 es hidrogeno o (C1-15)acilo; y las líneas de puntos indican enlaces opcionales.
ARP000103625A 1999-07-16 2000-07-14 Androgenos oralmente activos. AR024746A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99202348 1999-07-16

Publications (1)

Publication Number Publication Date
AR024746A1 true AR024746A1 (es) 2002-10-23

Family

ID=8240463

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000103625A AR024746A1 (es) 1999-07-16 2000-07-14 Androgenos oralmente activos.

Country Status (28)

Country Link
US (3) US6313108B1 (es)
EP (1) EP1203011B1 (es)
JP (1) JP2003505394A (es)
KR (1) KR20020092890A (es)
CN (1) CN1360589A (es)
AR (1) AR024746A1 (es)
AT (1) ATE257159T1 (es)
AU (1) AU770412B2 (es)
BR (1) BR0012489A (es)
CA (1) CA2379223A1 (es)
CO (1) CO5200765A1 (es)
CZ (1) CZ2002192A3 (es)
DE (1) DE60007530T2 (es)
ES (1) ES2213596T3 (es)
HK (1) HK1043797A1 (es)
HU (1) HUP0201952A3 (es)
IL (1) IL147332A0 (es)
MX (1) MXPA02000601A (es)
NO (1) NO20020222L (es)
NZ (1) NZ516525A (es)
PE (1) PE20010330A1 (es)
PL (1) PL353007A1 (es)
RU (1) RU2002103883A (es)
SK (1) SK712002A3 (es)
TR (1) TR200200076T2 (es)
TW (1) TW548277B (es)
WO (1) WO2001005806A1 (es)
ZA (1) ZA200200106B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000059920A2 (en) * 1999-04-06 2000-10-12 Akzo Nobel N.V. Orally active 7.alpha.-alkyl androgens
AU4966101A (en) * 2000-03-31 2001-10-15 Us Gov Health & Human Serv Methods of making and using 7alpha,11beta-dimethyl-17beta-hydroxy-4-estren-3-one17beta-trans-4-m-butylcyclohexane carboxylate and 7alpha,11beta-dimethyl-17beta -hydroxyestr-4-en-3-one 17-undecanoate
US20030069215A1 (en) * 2001-03-30 2003-04-10 The Government Of The United States Of America, Methods of making and using 7a,11b-dimethyl-17b-hydroxy-4-estren-3-one 17b-trans-4-n-butylcyclohexane carboxylate and 7a,11b-dimethyl-17b-hydroxyestr-4-en-3-one 17-undecanoate
SK882003A3 (en) * 2000-07-28 2003-07-01 Akzo Nobel Nv 16alpha-substituted steroid compounds, pharmaceutical composition comprising same and their use
ATE321557T1 (de) * 2001-03-30 2006-04-15 Us Gov Health & Human Serv Verfahren zur herstellung von 7alpha,11beta- dimethyl-17beta-hydroxyestra-4, 14-dien-3-one, dessen 17-ester und pharmazeutische zubereitungen die sie enthalten
ES2336439T3 (es) * 2002-01-21 2010-04-13 N.V. Organon Proceso para la preparacion de 7-alfa-metilesteroides.
GB0304927D0 (en) * 2003-03-04 2003-04-09 Resolution Chemicals Ltd Process for the production of tibolone
PE20050677A1 (es) 2003-12-22 2005-10-04 Akzo Nobel Nv Esteroides con perfil androgenico y progestagenico mixto
UA89964C2 (ru) 2004-09-08 2010-03-25 Н.В. Органон 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ
WO2010043404A1 (en) * 2008-10-15 2010-04-22 Synthon B.V. Processes and intermediates for the production of fulvestrant
CA2835979C (en) * 2011-06-01 2018-05-01 Estetra S.A. Process for the production of estetrol intermediates
PT2714710T (pt) 2011-06-01 2016-07-12 Estetra Sprl Processo para a produção de intermediários de estetrol
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
BR112014008196B8 (pt) * 2011-10-07 2020-12-15 Estetra Sprl processo para a preparação de um composto da fórmula (i)
WO2015181116A1 (en) 2014-05-26 2015-12-03 Crystal Pharma, S.A.U. Process and intermediades for the preparation of 7-alkylated steroids
EP3310346B1 (en) 2015-06-18 2021-03-24 Estetra SPRL Orodispersible tablet containing estetrol
SI3310333T1 (sl) 2015-06-18 2020-08-31 Estetra Sprl Orodisperzibilna enota odmerka, ki vsebuje komponento estetrola
CA2988485A1 (en) 2015-06-18 2016-12-22 Mithra Pharmaceuticals S.A. Orodispersible tablet containing estetrol
KR102664563B1 (ko) 2015-06-18 2024-05-09 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 에스테트롤 성분을 함유하는 구강분해성 투여 단위
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
CN110603059B (zh) * 2017-02-23 2023-06-30 美国西门子医学诊断股份有限公司 化学发光雄烯二酮缀合物
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA712312B (en) * 1970-04-28 1972-01-26 Ochsner Med Found Alton 4,14-estradiene compounds

Also Published As

Publication number Publication date
HUP0201952A2 (en) 2002-10-28
WO2001005806A1 (en) 2001-01-25
IL147332A0 (en) 2002-08-14
NO20020222D0 (no) 2002-01-15
HK1043797A1 (zh) 2002-09-27
US6313108B1 (en) 2001-11-06
EP1203011B1 (en) 2004-01-02
DE60007530D1 (de) 2004-02-05
ZA200200106B (en) 2003-06-25
CZ2002192A3 (cs) 2002-06-12
PE20010330A1 (es) 2001-03-22
SK712002A3 (en) 2002-06-04
TW548277B (en) 2003-08-21
CO5200765A1 (es) 2002-09-27
US6541465B2 (en) 2003-04-01
TR200200076T2 (tr) 2002-04-22
NZ516525A (en) 2003-06-30
CA2379223A1 (en) 2001-01-25
US20020022609A1 (en) 2002-02-21
AU770412B2 (en) 2004-02-19
ES2213596T3 (es) 2004-09-01
JP2003505394A (ja) 2003-02-12
HUP0201952A3 (en) 2003-10-28
NO20020222L (no) 2002-01-25
CN1360589A (zh) 2002-07-24
ATE257159T1 (de) 2004-01-15
MXPA02000601A (es) 2002-07-30
RU2002103883A (ru) 2004-02-27
US6780854B2 (en) 2004-08-24
AU6562900A (en) 2001-02-05
US20030087886A1 (en) 2003-05-08
PL353007A1 (en) 2003-09-22
KR20020092890A (ko) 2002-12-12
EP1203011A1 (en) 2002-05-08
BR0012489A (pt) 2002-04-02
DE60007530T2 (de) 2004-12-23

Similar Documents

Publication Publication Date Title
AR024746A1 (es) Androgenos oralmente activos.
DE69724777D1 (de) Pentafluorobenzensulfonamiden und analoge
DE122010000035I2 (de) Substituierte thien-3-yl-sulfonylamino(thio)carbonyl-triazolin(thi)one
DK1382604T3 (da) Quinolinderivater med en azolylgruppe og quinazolinderivater
NO20023823L (no) Fremgangsmåte for tilvirkning og bruk av pyrrolopyrimidinon- derivater
NO20015226D0 (no) Tri-aryl syrederivater som PPAR reseptor ligander
ES2269465T3 (es) Compuestos heterociclicos de union a los receptores de la quimioquina.
DE60027015D1 (en) Pseudoerythromycin-derivate
PT1007523E (pt) Derivados indole e 2,3-di-ridroindole, sua preparacao e utilizacao
CY1111816T1 (el) Παραγωγο θειαδιαζολινης για την θεραπεια του καρκινου
TR200403436T2 (tr) Kristalin 1-metilkarbapenem türevleri.
BRPI0409376A (pt) derivados de indeno como agentes farmacêuticos
PT1204658E (pt) Agonistas benzofurilpiperazina de serotonina
ES496451A0 (es) Un procedimiento para la produccion de derivados de 1,2,3,4,5,6-hexahidro-6-fenil-azepino (4,5,b) indol.
CO5160345A1 (es) Nuevos androgenos oralmente activos derivados de 7 alfa- metil-19-nortestosterona
ECSP003572A (es) Androgenos oralmente activos
ES2195500T3 (es) Dereivados del 2-indanometanol y su utilizacion a titulo de ingredientes perfumantes.
MY139258A (en) Carbamoyl-type benzofuran derivatives
AR024797A1 (es) Forma cristalina iii de la n-(4-(5-dimetilaminonaftalen-1-sulfonilamino)fenil)-3-hidroxi-2,2-dimetilpropionamida
ECSP003416A (es) Nuevos androgenos oralmente activos derivados de 7beta- metil-19- nortestosterona
DE69624459D1 (de) Kondensierte indan-derivate und ihre salze
TR200100475T2 (tr) N-İkameli azabisikloheptan türevlerinin üretimleri ve kullanımları.
DE60237652D1 (de) Variolinderivate und ihre Verwendung als Cytostatika
DE69828087D1 (de) Aminderivate
NO20025101L (no) Nye, heterosykliske forbindelser med antiinflammatorisk aktivitet

Legal Events

Date Code Title Description
FA Abandonment or withdrawal